We Position Oncology Drugs with Precision

JP Morgan 2017 1

Biotech Showcase 2017Peter Buhl Jensen CEO MD DMScOncology Venture

DRP™ Core Applications

2

PATIENT AS THE STARTING POINT

Pembrolizumab

cisplatin

Nivolumab

Anastrozole

5-FU

Bortezomib

Bosutinib

Brentuximab vedotin

Cabozantinib

Crizotinib

Carfilzomib

Cetuximab

Dasatinib

Denileukin diftitox

Erlotinib hydrochloride

Everolimus

Exemestane

Fulvestrant

Gefitinib

Ibritumomab tiuxetan

Imatinib mesylate

Ipilimumab

Lapatinib ditosylate

Doxorubicin

Nilotinib

Ofatumumab

Panitumumab

Pazopanib

Pertuzumab

Pralatrexate

Regorafenib

Rituximab

Belinostat

Sorafenib tosylate

Sunitinib malate

Tamoxifen

Temsirolimus

Toremifene

Tositumomab

131I-tositumomab

Trastuzumab

Tretinoin

Vandetanib

Vemurafenib

Vorinostat

Ziv-aflibercept

DRUG AS THE STARTING POINT

JP Morgan 2017

Digital Precision Gene Expression Pharmaco-omics - a Validated Drug Response Predictor Platform

Percentage of Patients for WhomDrugs are Ineffective

JP Morgan 2017 3

75%CANCER

• Monthly costs of newly approved Cancer drugs are

now >10.000 USD per patient

• Products for hard to treat cancers may be approved

with 20-30% response rate

• But only 2½ % of products in development get

approval

• Very often safety is ok and some patients benefit - but not enough to warrant approval

• No technology as broadly applicable and useful in ‘non-targeted drugs’ to find the patients who will

benefit until now

FDA 10/20/2013

Great in some patients

- and we willfind them

JP Morgan 2017 5

CONFIDENTIAL

6

Our Product Pipeline

JP Morgan 2017 7

Focused on EFFICACY CANCER INDICATION SCREENING PHASE 2 RANDOMIZED PHASE 3 OR PIVOTAL

END POINT

Metastatic Breast Durable Remission

Metastatic Breast (Cadila)Aimed at FDA EMA filing 3 years?

Prostate (Cadila) Durable Remission

Head & Neck (Cadila) Durable Remission

Esophagus (Cadila) Durable Remission

Skin (Cadila) Durable Remission

CANCER INDICATION SCREENING PHASE 2 RANDOMIZED PHASE 3 OR PIVOTAL

RESPONSE RATE BEFOREDRP SCREEN

Prostate 10% in unselected patients

Ovarian 13% in unselected patients

Liver Complete Responders in previous studies

CANCER INDICATION SCREENING PHASE 2 RANDOMIZED PHASE 3 OR PIVOTAL

STATUS

Multiple Myeloma Screening started. Phase 2 application submitted

Metastatic Breast Screening Started

2X Oncology et al.

JP Morgan 2017 8

SPV for Women's Cancers – seed round 3½ million secured and Series A commencing

Product Indication SCREENING PHASE 2 RANDOMIZED PHASE 3

OR PIVOTAL

RESPONSE RATE BEFORE DRP SCREEN

2X-111 TOP2# liposomal-GSH

Metastatic Breast41% had reduction in tumor in phase 2

2X-111 TOP2# Liposomal-GSH

Brain tumors (Glioblastoma)

40% had disease control, 14% had tumor reductions of >=20% in previous phase 2

2X- 121 PARP#Metastatic Breast

46% disease control., 7% PR in previous phase 1

2X-131 TOP1#Ovarian Cancer

~ 25 % partial response (PR) in ovarian cancer, ~40% PR and stable disease (SD) in breast cancer in previous phase 2

OV-SPV 2

Tyrosine kinase # SCREENING PHASE 2 RANDOMIZED PHASE 3 OR PIVOTAL

RESPONSE RATE BEFORE DRP SCREEN

Renal cancer Test in biopsies from phase 3 trial On par with commercial product

Liver cancer Test in biopsies from rand. phase 2 trial On par with commercial product

Understanding Complexity

JP Morgan 2017 9

To Solve Complex Problems

VS

Traditional Single point mutation Pathway view Oncology Venture - Data driven, Systems biology (network) view

SHORTEN Development Time

INCREASE Probability of Success REDUCE Capital Investment

INCREASE Sales

Understanding complexity to gain Precision

JP Morgan 2017 10

We Go Further than Competitors

JP Morgan 2017 11

In vitro Model

0 20 40 60 80 100

0.00

0.01

0.02

0.03

0.04

0.05

Prediction score

Den

sity

responders (CR+PR)

nonresponders (SD+PD)

P=0.11

P=0.11

Clinical Relevance Filter

0 20 40 60 80 100

0.00

0.01

0.02

0.03

0.04

0.05

Prediction score

Den

sity

responders (CR+PR)

nonresponders (SD+PD)

P=0.01

P=0.01

Utility in Clinic

0 20 40 60 80 100

0.00

0.01

0.02

0.03

0.04

0.05

Prediction score

Den

sity

responders (CR+PR)

nonresponders (SD+PD)

P=0.003

P=0.003

Drug Specific

DRP™ Biomarkers

Validating DRP™

JP Morgan 2017 12

- 32 clinical retrospective trials of many approved anti-cancer drugs

- 80% success rate robust biomarkers

- Bio markers enable selection of likely responders to enroll in clinical trials

LEVEL 1: generally sufficient for CE-IVD labeling / FDA: prospective trial(s) w/archival samples

LEVEL 2: strong data set, requires a confirmatory study: blinded, prospective trial with archival samples DRP™

DRP™ Usage Example

JP Morgan 2017 13

Predicting Who Should Have 5FU

Time (DAYS)

5FU

Survivalwithoutchemotherapy

2X

SUR

VIV

AL

Colon Cancer survival doubled

Cisplatin DRP™ in OV Lung Cancer Study

JP Morgan 2017 14

Valid for all indications

Bottom 50%

Top 50% p = 0.08 HR = 1.9

Top 20% p = 0.08 HR = 2.5

Top 10% p = 0.05 HR = Inf

P-values shown are for the logrank test. The more sensitive Cox proportional hazards regression gives a univariate p=0.007 and a multivariate(Including age, stage & histo) p=0.013

The 10% with the best cisplatin DRP™ ALL survived

Lung Cancer survival doubled

2X

Scalable Patient Selection with DRP™

JP Morgan 2017 15

>1100

20

JP Morgan 2017 16

Intelligent Targeted Cisplatin

• Lipid-based, nano-encapsuled formulation preciselydelivers cisplatin at tumor site

• Now including patients selected via DRP™ in phase 2study

• Activity seen in Breast, Esophagus, Skin and ColonCancer

• Partnership with Cadila: four phase 2 studies, onephase 3 study

• Market for Breast Cancer treatment ~ 8 billion USD2014, expected to reach 18 billion USD by 2022

Complemented by LiPlaCis DRP™ for patient population enrichment

JP Morgan 2017 17

Immuno-Oncology Drug with Unique MOA

• Imitates T-cells, inducing apoptosis of malignant cells

• Now screening Multiple Myeloma patients for afocused phase 1b/2 trial

• Big demand for MM treatment: market value 2014 over7 billion USD

• Cancer immunotherapy drug market estimated to 35billion USD by 2023

Complemented by APO010 DRP™ for patient population enrichment

APO010 Mechanism of Action

JP Morgan 2017 18

Tested in Over 1300 Patients - Effective for Several Indications

• Semi-synthetic drug, originating from natural productisolated from fungus Omphalotus Illudens

• Exerts anti-tumor activity by producing DNA adductsthat can only be repaired by the TC-NER pathway

• Screening patients to include in P.O.C. study.Focused phase 2 multi-center trial in SE & DK to beinitiated during spring 2017

• Market for Prostate Cancer drugs expected to triplefrom 2,5 billion USD 2013 to 7,6 billion in 2022

• Average treatment cost USD 40´/patient --> significantpotential for Irofulven

Complemented by Irofulven DRP™ for patient population enrichment

OV Business Facts

JP Morgan 2017 19

• Oncology Venture was formed in 2012 by Danish andUS oncology specialists, as a spin-off to MedicalPrognosis Institute (MPI.ST)

• Listed as Oncology Venture AB , Stockholm, Sweden onJuly, 2015 (OV.ST)

• Initial tock share rate: SEK 7.40

• Stock share rate per January 7, 2017: SEK 52.5

• 3 capital raises in 18 months,

• Raised a total of 7 million USD at 7.4, 10 and 29 SEK

• Market value per January 7, 2017: 60 million USD

We offer 2 types of investments in Oncology Precision

JP Morgan 2017 20

Oncology Venture listed in Stockholm (OV.ST)

SPV’s 2X Oncology Private US company based in Boston

with 3 promising phase 2 products

Women’s Cancers – Series A

OV-SPV2 Private Danish company w. Big Pharma TKI

New SPV’s New Product Opportunities

SHORTEN Development Time

INCREASE Probability of Success

REDUCE Capital Investment

INCREASE Sales

The Vision

JP Morgan 2017 21

Plans Going Forward

Help cancer patients get the accurate treatment right away

Create a global business based on the unique access to response prediction technology

Let’s Talk!

ULLA Buhl

Oncology Venture

Chief Operating Officer

Founder

JAMES Cullem

Oncology Venture

Vice President, Corporate Development

+1 (978) 500-0863

NIKOLAJ Buhl Jensen

Oncology Venture

CFO

PETER Buhl Jensen

Oncology Venture

CEO

Founder